uploads///Analysts Reco ATRA

Where Atara Biotherapeutics Stands This January: Analyst Ratings

By

Jan. 31 2018, Updated 3:07 p.m. ET

Company overview

Incorporated at Delaware in 2012, Atara Biotherapeutics (ATRA) is a company focused on developing novel T-cell immunotherapy treatment options for patients suffering from cancer and multiple sclerosis.

Atara’s allogenic T-cells are engineered from donors with healthy immune functions. This allows for a speedy delivery from inventories to patients (within three to five days) without the requirement of pretreatment. The company’s T-cell immunotherapies are designed to identify and eliminate cancerous cells without affecting healthy cells.

Article continues below advertisement

Analyst ratings

Of the six analysts covering Atara Biotherapeutics in January 2018, four analysts have given the stock a “buy” or a higher rating, while two analysts have given it a “hold” rating. The mean rating for the stock is 1.83, with a target price of $34.2.

Notably, Atara Biotherapeutics makes up about 0.04% of the Vanguard Russell 2000 ETF’s (VTWO) total portfolio holdings.

Peer ratings

By comparison, of the 26 analysts covering Amgen (AMGN) in January 2018, 12 analysts have given the company a “buy” or a higher rating, while 14 analysts have given it a “hold” rating. The mean rating for the stock is 2.35, with a target price of $192.8.

Of the 31 analysts covering Celgene (CELG) in January 2018, 17 analysts have given the stock a “buy” or a higher rating, while 13 analysts have given the stock a “hold” rating, and only one analyst has given it a “sell” rating. The mean rating for the stock is 2.19, with a target price of $123.7.

Of the 23 analysts covering Merck (MRK) in January 2018, 14 analysts have given the stock a “buy” rating, while nine analysts have given it a “hold” rating. The mean rating for the stock is 2.13, with a target price of $66.8.

In the next part of the series, we’ll take a look at Atara Biotherapeutics’ product pipeline.

Advertisement

More From Market Realist

  • 100 Thieves founder Matthew Haag
    Company & Industry Overviews
    Why Growing Esports Company 100 Thieves Isn't Publicly Traded
  • Bitski art and logo
    Company & Industry Overviews
    NFT Platform Provider Bitski Isn’t Publicly Traded
  • who are palantir customers
    Company & Industry Overviews
    Palantir Customers Are Large Defense and Commercial Institutions
  • Grain trucks waiting to be loaded and Archer Daniels logo
    Company & Industry Overviews
    Archer Daniels Stock Is a Buy Amid Price Dip and Big Announcement
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.